Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Dana-Farber-Cancer Institute Inc.

The Broad Institute, Inc.

Bayer Pharma Aktiengessellschaft

Stephan Siegel

Mark Jean Gnoth

Ulrich Rester

Andreas Wilmen

Niels Svenstrup

Stefan Heitmeier

Adrian Tersteegen

Susanne Röhrig

Norbert Schmees

Joachim Kuhnke

Matthew Meyerson

Ursula Mönning

Michael Sperzel

Dmitry Zubov

Amaury Ernesto Fernandez-Montalvan

Heidi Greulich

Michael Gerisch

Bernard Jacques Haendler

Daniel Korr

Pascale Lejeune

Bethany Kaplan

Jochen Strayle

Ulrich Klar

Dieter Lang

Ulf Bömer

Knut Eis

Markus Berger

Kai Thede

Christoph Gerdes

Anja Buchmüller

Arwed Cleve

Roland Neuhaus

Detlev Sülzle

Volker Schulze

Hartmut Schirok

Marcus Bauser

Simon Holton

Clara Christ

Michael Härter

Kirstin Petersen

Keith Graham

Stefan Nikolaus Gradl

Swen Allerheiligen

Antonius Ter Laak

Georges Von Degenfeld

Ulrike Röhn

Jens Schröder

Dieter Moosmayer

Holger Steuber

Franziska Siegel

Elke Dittrich-Wengenroth

Martin Krüger

Michael Niehues

Uwe Eberspächer

Julia Strassburger

Daniel Gallenkamp

Matthias Busemann

Stefan Bäurle

Manfred Husemann

Jörg Weiske

Hermann Künzer

Uwe Saatman

Uwe Saatmann

Carlo Stresemann

Sabine Krause

Hassan Youssef Harb

Phi Manh Dinh

Eis Knut

Hermann KÜNZER

Jochen Stayle

Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R, R, R, R, R, R, R, R, Rand X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients. 

4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R, R, R, R, R, R, R, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

2,3-benzodiazepines

The present invention relates to BET-protein-inhibitory, in particular BRD4-inhibitory 5-aryltriazoloazepines of the general formula (I) in which R, R, Rand Rhave the meanings given for the general formula (I),to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.

BET protein-inhibiting 5-aryltriazoleazepines

The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.

Imidazo-, pyrazolopyrazines and imidazotriazines and their use

The invention relates to substituted imidazo- and triazolopyrimidines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of haematological disorders, preferably of leucopenias and neutropenias.

Substituted imidazopyrimidines and triazolopyrimidines

The invention relates to substituted pyridines and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of haematological disorders, preferably of leukopenia and neutropenia.

Substituted pyridines, and use thereof as GSK3 inhibitors

The invention relates to substituted triazolopyrimidines of the formula processes for their preparation, and their use for the treatment of hematological disorders.

Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines

The invention relates to novel substituted oxazolidinones, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases, and to the use thereof for producing medicaments for treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.

Substituted oxazolidinones and their use

Growing community of inventors

Berlin, Germany

Stephan Siegel